493 results about "Red blood cell" patented technology

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

The embodiment of the invention provides a continuous blood oxygen monitoring system in extracorporeal circulation and a control method thereof. The continuous blood oxygen monitoring system comprises a vein sensor, an artery sensor, a blood flow sensor, an oxygen sensor, a carbon dioxide sensor, a controller and a display, the vein sensor monitors the vein blood oxygen saturation degree; the artery sensor monitors arterial oxygen saturation and hematocrit; the blood flow sensor monitors the blood flow of the artery pipeline; the oxygen sensor monitors the oxygen concentration of the oxygenator; the carbon dioxide sensor monitors the carbon dioxide concentration of the oxygenator; the display provides an interaction control, responds to a trigger operation acting on the interaction control, sends an interaction instruction to the controller, and updates information displayed in an interaction interface according to the control of the controller; the controller receives the interaction instruction and executes processing corresponding to the interaction instruction; the processing includes controlling display information of the display; the display information comprises information corresponding to the monitoring parameters. The scheme ensures the safety and effectiveness of the treatment process.

To improve measurement accuracy.A concentration measurement device includes: an absorbance measurement unit configured to measure absorbance in a plurality of different wavelength regions for a mixed liquid in which different liquids are mixed; and a control unit configured to correct a concentration of at least one liquid on the basis of absorbance in the plurality of different wavelength regions. The absorbance measurement unit measures absorbance in two wavelength regions. The absorbance measurement unit measures absorbance in a spectrum. Particles contained in one of the different liquids are different from particles contained in another of the different liquids. Each of the different liquids is a suspension or a solution. The mixed liquid includes a white blood cell suspension and a red blood cell suspension. The control unit calculates a mixing ratio of a liquid mixed in the mixed liquid, from absorbance in the plurality of different wavelength regions. The control unit corrects the absorbance on the basis of a mixing ratio of a liquid mixed in the mixed liquid.

The invention relates to the technical field of biological and medical diagnosis, in particular to a biomarker for predicting whether a patient suffering from pyotoxic myocardial injury has a short-term death risk or not and application of the biomarker, and the biomarker is the ratio of erythrocyte distribution width to albumin. According to the method, retrospective queue research design is adopted, two data sets, namely MIMIC-IV and eICU-CRD, are used, suppurative myocardial injury patients meeting conditions are included, covariants such as baseline features, laboratory inspection results and complication information of the patients are collected, the patients are divided into two groups according to RAR medians, the relation between RAR and short-term death of the patients is analyzed by adopting multiple statistical methods, and the accuracy of the short-term death of the patients is improved. A risk prediction model of short-term death of the patient suffering from the pyotoxic myocardial injury is constructed, so that a clinician can identify the patient suffering from the pyotoxic myocardial injury with high death risk in an early stage, a personalized treatment strategy can be formulated more accurately, the survival rate of the patient suffering from the pyotoxic myocardial injury is increased, and the method has a wide application prospect.

Fluid analyzation devices, methods, and systems are disclosed including an analyzation device comprising a sample vessel having an outer surface, a microchannel within the confines of the outer surface, a first port extending through the outer surface to the microchannel, and a second port extending through the outer surface to the microchannel; and an piezo transducer bonded to the outer surface of the sample vessel to form a monolithic structure, the piezo transducer configured to emit ultrasonic acoustic waves having a first frequency, a second frequency, and a third frequency into and / or to a blood sample within the microchannel, the first frequency configured to begin separation of red blood cells and plasma in the blood sample, the second frequency configured to complete separation of the red blood cells and plasma, and the third frequency configured to rupture cell walls of the blood cells producing a lysed blood sample.

The present invention relates to systems and methods for optimizing plasma collection volume. A plasma withdrawal system and a method for operating a plasma withdrawal system are provided by which the volume / weight of the anticoagulated plasma collected is optimized. In one example, a nomogram is provided that utilizes the donor hematocrit to calculate the volume / weight of raw plasma within a plasma product having a maximum volume allowed by the FDA nomogram. In a plasma withdrawal process having multiple collection phases followed by a reinfusion cycle in which concentrated red blood cells are returned to the donor, the volume of plasma product to be collected is calculated prior to the start of each collection cycle to account for the increasing hematocrit of the donor, resulting in a greater total volume of plasma product to be collected during the plasma withdrawal process.

Disclosed in the present application are an HCT prediction method and system, a device, and a medium. Photons in a photon group are emitted into an extracorporeal circulation blood model so that the photons are reflected, scattered, or absorbed during movement. The extracorporeal circulation blood model is a model constructed on the basis of the thickness of an extracorporeal circulation tube, the thickness of the blood, and the distance from a light source generator to a detector. Light intensity data corresponding to photons reaching the detector are acquired. The acquired light intensity data are input into a prediction model to obtain a hematocrit (HCT) prediction value. The prediction model is a model constructed on the basis of a BP neural network and the relationship between light intensity and HCT. The prediction model combining simulation and neural network increases the data volume, achieves continuous non-invasive estimation of HCT by means of algorithm model optimization, and improves the accuracy of HCT prediction.

The invention provides autologous platelet-containing plasma gel and a preparation method and application thereof, and relates to the technical field of biological medicine and tissue engineering.The preparation method comprises the following steps that peripheral venous blood of a patient is extracted and added into a centrifugal tube mixed with a sodium citrate anticoagulant; putting the centrifugal tube into a centrifugal machine for centrifuging, and taking upper-layer plasma; wherein the upper-layer plasma refers to plasma between the upper-layer liquid level and the lower-layer red blood cell layer by 1mm; the centrifugal speed ranges from 1300 r / min to 1700 r / min; the centrifugation time is 3-5 min; under a sterile condition, preparing a calcium gluconate / thrombin mixed solution; and dropping the calcium gluconate / thrombin mixed solution into the upper plasma, mixing, and solidifying to obtain the autologous platelet-containing plasma gel. After one-time centrifugation, upper-layer full-layer plasma is extracted, the volume of the prepared gel is far larger than that of a traditional method, the utilization rate of whole blood platelets and fibrinogen is close to 100%, and regeneration and repair of large-area tissue wounds can be met.

The present invention provides a traditional Chinese medicine composition for clearing heat, removing blood stasis, stopping bleeding and regulating menstruation, and a preparation method thereof, relating to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition of the present invention comprises the following components: catalpol, aucubin, β-sitosterol, emodin, chrysophanol, sanguisorba officinalis extract, Panax notoginseng saponins, septamine, cuttlefish scaly, rubiacin, typhaneuroside, and p-coumaric acid; the components synergistically work together to significantly reduce plasma prothrombin time and plasma recalcification time, and significantly reduce the whole blood viscosity, plasma viscosity, and hematocrit of rats with blood stasis syndrome. The traditional Chinese medicine composition of the present invention is used in the preparation of drugs for menstrual disorders or menstrual bleeding and metrorrhagia, and has a significant therapeutic effect on irregular menstruation, excessive menstrual bleeding, or metrorrhagia.

The invention features polypeptides that include an extracellular ActRIIA variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIA variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving low red blood cell levels, e.g., anemia or blood loss; fibrosis; or pulmonary hypertension.

The utility model discloses a blood platelet rich plasma preparation device which comprises a middle sleeve, an upper storage body, an upper storage cover, a lower storage body and a lower storage cover, a hyperbolic PRP channel and a hyperbolic red blood cell channel are arranged in the upper storage body and the lower storage body respectively, an upper locking bolt and a lower locking bolt are fixed in the middle sleeve, and after the upper locking bolt and the PRP channel are locked in a matched mode, the upper locking bolt and the lower locking bolt are locked in a matched mode. The upper storage body and the upper storage cover form a PRP storage chamber, after the lower locking bolt and the red blood cell channel are matched and locked, the lower storage body and the lower storage cover form a red blood cell storage chamber, the middle sleeve is a plasma storage chamber, a PRP suction opening is formed in the upper storage cover, and the required PRP amount is accurately extracted through the suction opening through the needle head. According to the blood separation device, two times of centrifugal separation can be carried out under the condition that blood is not exposed to air, the blood separation concentration is high, and the PRP extraction amount is accurate.

The invention provides a Kawasaki disease coronary artery disease risk dynamic prediction algorithm and an automatic upgrading system. The Kawasaki disease coronary artery lesion risk dynamic prediction algorithm and the automatic upgrading system comprise the following steps: a, acquiring clinical data of a Kawasaki disease child patient, including data of disease date, sex, month age, serum sodium level, D dimer, erythrocyte distribution width, prothrombin time and C-reactive protein biomarker; according to the Kawasaki disease coronary artery disease risk dynamic prediction algorithm and the automatic upgrading system, through combination of clinical features and gene data of Kawasaki disease children patients, a plurality of machine learning algorithms are used, and an efficient and accurate CAL risk prediction model is constructed. The model combines a plurality of key clinical indexes such as serum sodium level, CRP and D dimer and gene data such as SNP markers such as SIGLEC8-CEACAM18 and PPP1R1C, and the sensitivity and specificity of risk prediction are remarkably improved.

The utility model discloses a device for preparing platelet-rich plasma suspension and gel containing blood cells. Comprising a fixing frame, at least one rapid clamping pipe clamp installed on the fixing frame, a vacuum centrifugal pipe clamped in the rapid clamping pipe clamp, and two suction devices capable of being inserted into the centrifugal pipe from the top or the bottom of the centrifugal pipe. The pusher is used for pushing the aspirator to be inserted into the centrifugal tube; the rotating mechanism is used for driving the pusher to rotate so as to enable the aspirator to face the top or the bottom of the centrifugal tube; the utility model solves the problems of blood pollution, manual operation error and low extraction rate in the manual operation process in the prior art, retains all blood platelets and white blood cells in the blood, retains red blood cells in normal proportion and most plasma proteins, and improves the extraction efficiency. Moreover, the concentration of platelets and leukocytes is constantly about 4 times of the concentration of blood of common normal people, the functions of erythrocyte components are reserved, and the functional effects of various components in the blood can be better exerted.

The invention relates to a hypoperfusion oxyhemoglobin saturation detection method based on dynamic light compensation, which comprises the following steps of: constructing a combined characteristic relation based on multi-wavelength reflection intensity and fluctuation amplitude, and dynamically judging the optical sparseness of tissues, namely optical characterization of erythrocyte density in the tissues; reversely deducing the current perfusion degree through the morphological characteristics of the reflection waveform; establishing a perfusion optical index; analyzing the dynamic change trend of light reflection in a past period of time by adopting a time sequence modeling mode; an LED driving strategy is dynamically adjusted, and a light supplementing behavior similar to a physiological rhythm is formed in a step-by-step climbing mode, a pulse stimulation mode and a period maintaining mode; each light supplementing action is regarded as physiological stimulation; dynamic form similarity discrimination is introduced, whether tissue response is really caused by light supplement each time is quantified, and real physiological fluctuation and noise disturbance are distinguished; for low-response light supplement, the light supplement intensity is reduced in a feedback manner; on the contrary, key deformation features are extracted from high-response light supplement for signal reconstruction, and the signal recognition capability in the low-perfusion environment can be enhanced.

The invention discloses an optical fiber optical tweezers system for realizing three-dimensional control of red blood cells in a living blood vessel across the air, and relates to the technical field of photoelectricity, and the system comprises a laser, optical fiber optical tweezers, a six-axis fine adjustment frame, an objective table and an imaging observation assembly. The laser device outputs laser, long-distance focusing is achieved through the optical fiber tweezers with the output end being of a three-section gradual change structure, the focal length is larger than or equal to 30 microns, the focusing point can cross epidermal tissue and a blood vessel wall, an optical potential hydrazine is formed in a living blood vessel, and light gradient force is applied across the air to achieve stable capturing of flowing red blood cells. The optical fiber optical tweezers are adjusted through the six-axis fine adjustment frame, and three-dimensional control over the position of the captured red blood cells can be achieved. The imaging observation assembly carries out real-time imaging, and operation visibility is guaranteed. According to the invention, simultaneous capture and serial assembly can be carried out on a plurality of red blood cells in a living blood vessel. The system has the advantages of compact structure, biocompatibility, stable control and the like, and is expected to provide a powerful tool for function research, microcirculation analysis and the like of red blood cells in living blood vessels.

A blood separation device includes a pump system, a separator, and a controller. The controller is programmed to execute a blood separation procedure including a red blood cell collection stage in which blood is conveyed into the separator, red blood cells are separated from the blood in the separator, and the separated red blood cells are conveyed from the separator into a collection container. The red blood cell collection stage is ended when a target volume of blood has been separated in the separator. The controller then determines a percentage of the red blood cells from the target volume of blood that have been collected in the collection container based on the volume of red blood cells and the hematocrit of the fluid in the collection container, a volumetric flow rate of pure red blood cells in the blood conveyed into the separator, and the procedure time.

The present disclosure relates to systems and methods for measuring glycated A1c hemoglobin. A glycated hemoglobin level measuring system includes a sample testing apparatus having a microchannel that compresses a blood sample traveling through, a first pair of electrodes coupled to the microchannel, and a second pair of electrodes coupled to the microchannel. The glycated hemoglobin level measuring system further includes an analysis apparatus having sensors coupled to the first and second pairs of electrodes and configured to calculate a travel time taken by a red blood cell to pass through the first and second pairs of electrodes. The glycated hemoglobin level measuring system can use the travel time to measure a rigidity of the red blood cells and the corresponding glycated hemoglobin level.

The abnormal red blood cell parameter detection method and the identification AI training method thereof comprise the following steps: shooting a tiled microscopic examination sample to obtain an image; normal red blood cells and abnormal red blood cells in the image are identified and marked, AI training is carried out by using a marked picture, and an AI feature data set A is obtained and comprises normal red blood cell features and abnormal red blood cell features. Identifying abnormal red blood cells in a selected area S1 in the microscopic examination sample image by using an AI identification algorithm to obtain the total number NUMS1 of the abnormal red blood cells in the selected image; and the AI recognition algorithm recognizes abnormal red blood cells according to the abnormal red blood cell feature data set. The abnormal red blood cell collection efficiency is improved through multiple processing processes, and the AI training efficiency for identifying the abnormal red blood cells is improved. The method has the capability of collecting data of abnormal red blood cells of unknown types, and provides deeper information for clinical research. Abnormal red blood cell recognition is completed through advanced AI computing power, and analysis is more efficient and accurate.

The invention belongs to the field of biological materials, and particularly relates to hydroxyapatite nanofiber / biopolymer composite hemostatic sponge capable of rapidly absorbing liquid and expanding as well as a preparation method and application of the hydroxyapatite nanofiber / biopolymer composite hemostatic sponge. The hemostatic sponge is formed by cross-linking and compounding hydroxyapatite nanofibers and biopolymers, the chemical composition of the hydroxyapatite nanofiber is hydroxyapatite, the diameter of the hydroxyapatite nanofiber is 10-100 nm, and the length of the hydroxyapatite nanofiber is 10-500 [mu] m; the biopolymer is one or more of chitosan, carboxymethyl chitosan, hydroxypropyl chitosan, chitosan quaternary ammonium salt, chitosan hydrochloride, hyaluronic acid, alginic acid, gelatin and collagen; the hydroxyapatite nanofiber in the hemostatic sponge accounts for 10wt%-90wt% of the total mass of the sponge. The hemostatic sponge disclosed by the invention has excellent imbibition expansion capacity, relatively high imbibition expansion pressure, good erythrocyte and platelet adsorption capacity and good blood compatibility and biocompatibility.

The rejection monitoring device comprises a bottom cylinder and a monitoring assembly, the monitoring assembly comprises a liquid inlet pipe connected to the outer side of the bottom cylinder, a partition plate is arranged on the outer side of a middle line of a connector of the liquid inlet pipe and the bottom cylinder, a pair of guide plates is arranged at the bottom end of the partition plate, and liquid guide holes are vertically formed in the two guide plates; a motor is arranged on the inner bottom wall of the bottom cylinder, the output shaft end of the motor is coaxially connected with a tray, a plurality of pairs of analysis cylinders are uniformly arranged on the tray, and the bottom ends of the two liquid guide holes are respectively aligned with any pair of analysis cylinders in the vertical direction; the urine and blood states of a patient can be regularly detected through the arranged monitoring assembly, the operation difficulty of medical staff is reduced, meanwhile, the sampling time and the time difference for obtaining the detection result can be shortened, and then the monitoring effect of the monitoring assembly is improved; red blood cells and proteins or other biochemical indexes in urine of a patient can be detected through the detection agent filled in the analysis cylinder.

Therapeutic compounds for red blood cell-mediated delivery of an active pharmaceutical ingredient to a target cell are described. The therapeutic compounds are configured to bind CD47 on the surface of a red blood cell and to be subsequently transferred to CD47 on the surface of the target cell, the therapeutic compound ultimately being internalized by the target cell via endocytosis. The target cell may be a cancer cell.

Quinones for use in therapeutic recovery, normalization and / or improvement of ATP in mitochondrial deficient cells, such as red blood cells, are disclosed. Particular examples are use in the treatment of erythrocystic diseases, especially in the treatment of erythrocyte metabolic defects, such as erythrocyte glycolysis defects. This treatment increases ATP in non-mitochondrial cells. Thus, the present invention relates to quinones for use in the treatment of diseases or conditions associated with or caused by a glycolytic deficiency in red blood cells.

The invention discloses a preparation method of metal organic framework armored red blood cells and an application of the red blood cells in cryopreservation, an MOF armor coated on the surfaces of the red blood cells in situ in one step is prepared in a physiological environment, the red blood cells can be effectively prevented from being damaged by freezing induction, and meanwhile, the natural oxygen carrying function of the red blood cells is kept. The unique ice control capacity of the MOF armored red blood cells is explored, including inhibition of recrystallization of ice, induction of smoothness of the ice front, reduction of formation of sodium chloride eutectic and acceleration of ice melting, a novel design strategy is provided for an MOF-based ice control material, and the future prospect of the MOF-based ice control material in the field of efficient ice inhibition is possibly widened.

This invention belongs to the field of pharmaceutical technology, specifically relating to the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke. By constructing a mouse model of heatstroke-induced myocardial injury and observing indicators such as rectal temperature, blood routine tests, blood biochemistry, oxidative stress, and cardiac function, this invention found that lemon balm glycosides can significantly reduce the increase in rectal temperature caused by heatstroke in mice, increase the content of red blood cells and albumin in plasma, and reduce the level of oxidative stress in myocardial cells. Therefore, the application of lemon balm glycosides in the preparation of drugs for the prevention or treatment of heatstroke is proposed.

A system and method of isolating extracellular vesicles. The method includes loading one or more of blood or bone marrow into an input port of a concentration system and centrifuging one or more of the blood or bone marrow to separate one or more of red blood cells, platelet poor plasma, or platelet rich plasma / bone marrow concentrate fractions via a centrifuge device. The method further includes pumping one or more of bone marrow / platelet rich plasma fractions and platelet poor plasma fractions into a receptacle of the concentration system and adding a concentrated aqueous two-phase solution to one or more of the bone marrow concentrate / platelet rich plasma fractions and platelet poor plasma fractions. The method also includes drawing the concentrated aqueous two-phase solution and one or more of the bone marrow concentrate / platelet rich plasma fractions or platelet poor plasma fractions back into the centrifuge device to isolate one or more of extracellular vesicles and platelet rich plasma / bone marrow concentrate fractions.

The invention discloses a Vismodegib and BMS-1 co-loaded bionic nano delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the preparation method disclosed by the invention, Vismodegib and BMS-1 are prepared into a nano-micelle core, and then red blood cell vesicles are utilized to prepare the bionic nano delivery system co-loaded with Vismodegib and BMS-1. Experiments prove that the bionic nano delivery system prepared by the invention inhibits the growth of mouse in-situ tumors and the formation of lung / liver tumor metastasis lesions, and the effect is obviously superior to that of Vismodegib or BMS-1 used alone, Vismodegib and BMS-1 combined use and Vismodegib or BMS-1 loaded nano delivery carriers. The invention provides a new idea for clinical treatment of triple negative breast cancer.

The present invention discloses a functional solid beverage for resisting altitude sickness and a preparation method thereof. The raw materials of the solid beverage include yak spleen small molecule polypeptide, yak milk small molecule polypeptide, taurine, phosphatidylserine, crystalline fructose and flaxseed; wherein the amino acid sequence of the yak spleen small molecule polypeptide is shown as SEQ ID NO.1, and the amino acid sequence of the yak milk small molecule polypeptide is shown as SEQ ID NO.2. The functional solid beverage of the present invention promotes oxygen carrying and improves the oxygen transport efficiency of red blood cells by reducing the deformation and adhesion of red blood cells caused by plateau exposure, thereby effectively preventing and alleviating altitude sickness such as headache, nausea, fatigue, etc. The product is portable and easy to use, the ingredients are safe and harmless, and the effect has been verified to be significant through experiments. The functional solid beverage of the present invention provides scientific and effective health protection for people entering high-altitude areas, and has broad market prospects and application value.

This invention relates to a method and application for enriching circulating tumor cells (CTCs) based on ambient temperature mechanical perfusion technology, belonging to the field of biomedical technology. The method comprises the following steps: flushing the liver resected during liver transplantation via the portal vein and hepatic artery, connecting it to an ambient temperature mechanical perfusion loop, and performing in vitro perfusion using simulated blood perfusion fluid; when perfusion exceeds 2 hours and the lactate content drops to <5 mmol / L, collecting the simulated blood perfusion fluid; and sequentially subjecting the simulated blood perfusion fluid to centrifugation, red blood cell removal, and white blood cell removal to obtain enriched circulating tumor cells (CTCs) for liver cancer. A human liver cancer ex vivo organ perfusion model is constructed using NMP technology to fully recreate the tumor microenvironment and CTC generation process, and the large volume of perfusion fluid is processed to achieve efficient enrichment of CTCs.

The present disclosure describes anti-inflammatory properties of red blood cell extracellular vesicles, e.g., as mediated by heme, hemoglobin and / or phosphatidylserine content. The present disclosure describes technologies useful for the treatment of inflammatory diseases, disorders, or conditions (e.g., atherosclerosis).

The application belongs to the technical field of antibacterial medicine, and particularly relates to a cinnamaldehyde-modified polypyridine ruthenium complex for inhibiting hemolysis, a preparation method and application thereof. The cinnamaldehyde-modified polypyridine ruthenium complex has a structure as shown in formula I. 1 , formula I 2 or formula I 3 The cinnamaldehyde-modified polypyridine ruthenium complex can effectively reduce the hemolysis of red blood cells caused by toxins released by Staphylococcus aureus, and the ruthenium complex does not induce the drug resistance of bacteria, and can significantly increase the sensitivity of Staphylococcus aureus to aminoglycoside antibiotics.